- Home
- KOPN vs AVTX Comparison
KOPN vs AVTX Comparison
Compare KOPN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOPN
- AVTX
- Stock Information
- Founded
- KOPN 1984
- AVTX 2011
- Country
- KOPN United States
- AVTX United States
- Employees
- KOPN N/A
- AVTX N/A
- Industry
- KOPN Semiconductors
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KOPN Technology
- AVTX Health Care
- Exchange
- KOPN Nasdaq
- AVTX Nasdaq
- Market Cap
- KOPN 95.8M
- AVTX 88.4M
- IPO Year
- KOPN 1992
- AVTX 2015
- Fundamental
- Price
- KOPN $0.91
- AVTX $4.41
- Analyst Decision
- KOPN Strong Buy
- AVTX Strong Buy
- Analyst Count
- KOPN 4
- AVTX 7
- Target Price
- KOPN $2.63
- AVTX $34.33
- AVG Volume (30 Days)
- KOPN 3.1M
- AVTX 69.6K
- Earning Date
- KOPN 04-17-2025
- AVTX 05-12-2025
- Dividend Yield
- KOPN N/A
- AVTX N/A
- EPS Growth
- KOPN N/A
- AVTX N/A
- EPS
- KOPN N/A
- AVTX N/A
- Revenue
- KOPN $50,335,167.00
- AVTX $441,000.00
- Revenue This Year
- KOPN $10.45
- AVTX N/A
- Revenue Next Year
- KOPN $22.49
- AVTX N/A
- P/E Ratio
- KOPN N/A
- AVTX N/A
- Revenue Growth
- KOPN 24.61
- AVTX N/A
- 52 Week Low
- KOPN $0.56
- AVTX $4.44
- 52 Week High
- KOPN $2.17
- AVTX $17.49
- Technical
- Relative Strength Index (RSI)
- KOPN 41.68
- AVTX 29.58
- Support Level
- KOPN $0.81
- AVTX $4.59
- Resistance Level
- KOPN $0.94
- AVTX $5.85
- Average True Range (ATR)
- KOPN 0.11
- AVTX 0.85
- MACD
- KOPN 0.01
- AVTX -0.21
- Stochastic Oscillator
- KOPN 71.43
- AVTX 2.41
About KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).